Amarin Message Board


11 minutes ago

Dr. Bhatt is very impressive. He is speaking at AdCom, correct?

Amarin EVAPORATE Study Results

9 hours ago

Will the results of EVAPORATE be included at AdCom or does the embargo take precedence?

Amarin News

10 hours ago

New Study Shows Promise in Treating More Patients with World’s Smallest Pacemaker

6 hours ago

​Medtronic plc (NYSE:MDT) today announced results from the MARVEL 2 (Micra Atrial Tracking Using A Ventricular accELerometer) study showing that an investigational set of algorithms in the Micra Transcatheter Pacing System (TPS) significantly improves synchrony and cardiac function in patients with impaired electrical conduction between the chambers of the heart

Vascepa Script Numbers

4 days ago

Scripts for week ending 11/8/19 - More All-Time Highs

New Analysis Shows Icosapent Ethyl (Vascepa) Is Cost Effective and Offers Rare Finding of Better Outcomes at Lower Healthcare Costs When Used to Treat High-Risk Patients with Cardiovascular Disease or Diabetes and Other Risk Factors

10 hours ago

​Amarin Corporation plc (NASDAQ: AMRN) announced today a summary of results from a patient-level, cost-effectiveness analysis of icosapent ethyl (Vascepa®).1 This comprehensive analysis evaluated the cost-effectiveness of icosapent ethyl in reducing cardiovascular (CV) risk among high-risk patients

Amarin Commercial Expansion

1 week ago

There are currently 190 sales openings and it sounds like the hiring is progressing. A lot of investors take this movement as the company feeling good about expanded labeling and EVAPORATE trial results.

What is Vascepa used for and is it better than fish oil?

1 week ago

It is?

Adverse events (AE) occurring in ≥5% of VASCEPA patients and statistically more frequently with VASCEPA than placebo:

  • Peripheral edema (6.5% VASCEPA patients versus 5.0% placebo patients)
    • There was no significant difference in the prespecified adjudicated tertiary endpoints of new congestive heart failure which occurred in 4.1% of VASCEPA patients versus 4.3% of placebo patients, or in new heart failure requiring hospitalization, which occurred in 3.4% of VASCEPA and 3.5% of placebo patien…

Foamix and Menlo Therapeutics to Merge, Creating a Combined Company Focused on the Development and Commercialization of Therapeutics for Dermatologic Indications

10 hours ago

​Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) and Menlo Therapeutics Inc. (Nasdaq: MNLO) today announced that they have signed a definitive merger agreement to create a combined biopharmaceutical company focused on the commercialization and development of therapeutics to serve patients in the dermatology space. The Boards of Directors of both Foamix and Menlo have unanimously approved the transaction.

Could Vascepa be underpriced?

1 week ago

The Amarin Savings Program is a great deal and a lot of the StockTwits community has shown the pricing with the program, which is as little as $9 for 90 days. They say that pricing is saving patients up to $110 per month, or $330 for a 90-day prescription. That program is when using the Vascepa Savings Card.

I don't think this pricing without the savings card will last that long. Amarin is using it as a strategy to get more patients using the drug and I'm sure the list price will increase over t…

Amarin Patent Litigation for Vascepa

2 weeks ago

Patent case update & potential settlement "Hmmm"; knows Dr. Nissen is corresponding with FDA & Yee notes Nissen's STRENGTH trial is olive oil placebo (actually corn oil which may have OM6 probs) but FOIA not available, sees AMRN raising guidance to high end

Amarin Insider Buying

2 weeks ago

Love to see John Thero picking up more shares before AdCom!

Amarin Corporation PLC's President and CEO just picked up 11,601 shares

John F Thero, Amarin Corporation PLC's President and CEO and a director of the company, recently acquired 11,601 shares of the company. The buys took place at $2.50 per share, on October 28, 2019. Thero now owns 3,092,285 shares of the company. Thero operates out of Bridgewater, NJ.

Amarin Rumors

2 weeks ago

What are they saying on the IHUB AMRN board about buyout rumors?

ICER Gives Vascepa a B+ in Final Report

3 weeks ago